$GSK news
The latest GSK stock news: headlines, filings, AI summaries and sentiment for $GSK, updated around the clock.
- Wave Life Sciences Reports Strong Q3 2026 Results with Robust Cash Position and Clinical Progress
- Emma Walmsley Appointed as New CEO of HP
- HP Appoints Former GSK CEO Emma Walmsley as New Chief Executive Officer
- Pennsylvania Reports Nearly 1,400 Measles Cases and Five Deaths
- GSK Reports Q3 2026 Growth Driven by Specialty Medicines and HIV Portfolio
- GSK Announces Third Interim Dividend Increase to 17p Per Share
- GSK Reports Q3 Earnings Beat with Strong Specialty Medicines and HIV Sales Growth
- Market Outlook: Federal Reserve Interest Rate Decision and Key Earnings Reports
- Wave Life Sciences Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- GSK Q3 Earnings Preview: Analysts Forecast Significant Growth in Revenue and EPS
- Wave Life Sciences Reports Q3 Revenue Beat and Improved Earnings Per Share
- CSL Limited Appoints GSK Executive Deborah Waterhouse as Future CEO
- AnaptysBio and GSK Receive FDA Label Expansion for Jemperli in Rectal Cancer
- GSK Announces Over 1,200 Job Cuts in Belgium as Part of Restructuring Plan
- GSK Announces Over $800M Investment to Expand Operations and Create Jobs in Pennsylvania
- GSK-owned ViiV Healthcare's Cabenuva Succeeds in Late-Stage HIV Trial
- AbbVie Included in New 340B Rebate Pilot Program
- Big Pharma Companies Partner with Chinese Biotechs Amid Patent Expirations
- Wave Life Sciences to Receive $12M Milestone Payment from GSK
- $3.3 Million Philanthropic Commitments Support Good Jobs Initiative in Western North Carolina
- GSK Aims for £40 Billion Sales Target with Oncology Growth and Cost-Saving Plan
- GSK's China Licensing Deals, Electra Therapeutics' $300M IPO and Scholar Rock’s Drug Approval Highlight Biopharma Trends
- AstraZeneca's Tozorakimab Shows Strong Results in COPD Trials
- GSK Announces Job Cuts in Vaccine Manufacturing Restructuring
- High-Grade Debt Issuance Surpasses $57 Billion in Post-Labor Day Surge
- AstraZeneca's COPD Drug Shows Strong Trial Results and Blockbuster Potential
- HUTCHMED Announces Major Licensing Agreement with GSK for Experimental Cancer Therapy
- HUTCHMED Enters $1.3B Deal With GSK for Ex-China Rights to Preclinical Cancer Therapy HMPL-A830
- HutchMed Enters Licensing Deal with GSK for Cancer Therapy, Could Generate Up to $1.295 Billion
- Moderna Rises Despite GSK Advancing Competing mRNA Flu Vaccine
- Wave Life Sciences Reports Q2 2026 Financial Results and Clinical Progress
- GSK Announces Cost-Savings Plan Amid Q2 Earnings Beat
- GSK Launches $2.5 Billion Cost-Savings Program to Fund Drug Development
- GSK receives FDA approval for lung cancer drug Jideytro
- Trevi Shares Rise Following GSK's Discontinuation of Chronic Cough Therapy
- Stocks Making Significant Moves Midday: Travelers, GSK, Netflix and Others
- GSK Shelves Cough Therapy Following Trial Failure
- Spero Therapeutics Secures $105 Million Royalty Financing for SP001 Development
- GSK's Jemperli Shows Sustained Complete Clinical Response in Phase 2 Trial for Rectal Cancer
- UBS Maintains Neutral Rating on GSK Amid CEO Strategy Update
- GSK Partner Hansoh Reports Positive Late-Stage Cancer Trial for Risvutatug Rezetecan
- Amplia Appoints Brett Carter as Non-Executive Director
- GSK and Spero Therapeutics Receive FDA Approval for First Oral Carbapenem Antibiotic for Complicated UTIs
- GSK Launches Meningitis Awareness Campaign with Celebrity Advocates
- GSK Expands Eligible Population for Arexvy in Japan
- GSK and Ionis Report Positive Late-Stage Trial Results for Chronic Hepatitis B Drug
- GSK Completes $950M Acquisition of 35Pharma Inc.
- Omnicom Group Inc. Q1 2026 Earnings Call Summary
- GSK Reports Strong Q1 Earnings with Sales Growth and Guidance Reiteration
- GSK Reports Q1 2026 Financial Results Ahead of Expectations